JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blais, C.
Right arrow Articles by Adam, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blais, C., Jr.
Right arrow Articles by Adam, A.

Vol. 295, Issue 2, 621-626, November 2000

Protective Effect of Omapatrilat, a Vasopeptidase Inhibitor, on the Metabolism of Bradykinin in Normal and Failing Human Hearts1

Charles Blais, Jr., David Fortin, Jean-Lucien Rouleau, Giuseppe Molinaro and Albert Adam

Faculté de Pharmacie, Université de Montréal, Montréal, Québec, Canada (C.B., D.F., G.M., A.A.); and Division of Cardiology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada (J.-L.R.)

Because part of the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitors results from their protective effects on cardiac bradykinin (BK) metabolism, the purpose of this study was to define the metabolism of BK in normal and failing human hearts and to compare the effect of omapatrilat, a vasopeptidase inhibitor (VPI), which simultaneously inhibits both neutral endopeptidase (NEP) and ACE, with that of an ACE inhibitor. Exogenous BK at a nanomolar concentration was incubated alone, in the presence of an ACE inhibitor (ramiprilat, 36 nM), or in the presence of a VPI (omapatrilat, 61 nM) with left ventricular membranes prepared from normal donor hearts (n = 7), and hearts from patients with an ischemic (n = 11) or dilated (n = 12) cardiomyopathy (DCM). The half-lives calculated for BK alone (199 ± 60, 224 ± 108, and 283 ± 122 s; P = NS) exhibited similar values for normal, ischemic, and DCM heart tissues, respectively. Ramiprilat significantly increased the half-life of BK (P < .01), but the effect was similar for the three kinds of tissues (297 ± 104, 267 ± 157, and 407 ± 146 s, respectively; P = NS). The potentiating effect of the VPI omapatrilat on the kinetic parameter of BK (478 ± 210, 544 ± 249, and 811 ± 349 s, respectively) was greater than that of the ACE inhibitor (P < .01). Moreover, omapatrilat had a more important potentiating effect with DCM than normal heart membranes (P < .05). These results show that not only ACE but also and mainly NEP play an important role in the degradation of BK in human heart membranes. Omapatrilat, a VPI, has a greater protective effect on BK metabolism than that of a pure ACE inhibitor. Thus, inhibition of both ACE and NEP with omapatrilat could be more cardioprotective than ACE inhibition alone.

1 This study was supported by a Pharmaceutical Manufacturers Association of Canada-Medical Research Council of Canada grant (to A.A. and J.-L.R.) and by a scholarship from the Fonds de la recherche en santé du Québec (to C.B.).

0022-3565/00/2952-0621$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. E. Moreau, P. Dubreuil, G. Molinaro, M. Chagnon, W. Muller-Esterl, Y. Lepage, F. Marceau, and A. Adam
Expression of Metallopeptidases and Kinin Receptors in Swine Oropharyngeal Tissues: Effects of Angiotensin I-Converting Enzyme Inhibition and Inflammation
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1065 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
J. Varagic, D. Susic, M. Slama, and E. D. Frohlich
Omapatrilat Induces Profound Renal Vasodilation but Does Not Affect Coronary Hemodynamics
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 167 - 174.
[Abstract] [PDF]

Home page
 CirculationHome page
C.-H. Wang, N. Leung, N. Lapointe, L. Szeto, K. D. Uffelman, A. Giacca, J. L. Rouleau, and G. F. Lewis
Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats: Studies Comparing a Vasopeptidase Inhibitor, Angiotensin-Converting Enzyme Inhibitor, and Angiotensin II Type I Receptor Blocker
Circulation, April 15, 2003; 107(14): 1923 - 1929.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Azizi, M. Lamarre-Cliche, A. Labatide-Alanore, A. Bissery, T. T. Guyene, and J. Menard
Physiologic Consequences of Vasopeptidase Inhibition in Humans: Effect of Sodium Intake
J. Am. Soc. Nephrol., October 1, 2002; 13(10): 2454 - 2463.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J J V McMurray
Heart failure in 10 years time: focus on pharmacological treatment
Heart, October 1, 2002; 88(90002): ii40 - 46.
[Full Text] [PDF]

Home page
 HypertensionHome page
C. V. Maniu, D. M. Meyer, and M. M. Redfield
Hemodynamic and Humoral Effects of Vasopeptidase Inhibition in Canine Hypertension
Hypertension, October 1, 2002; 40(4): 528 - 534.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Corti, J. C. Burnett Jr, J. L. Rouleau, F. Ruschitzka, and T. F. Luscher
Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease?
Circulation, October 9, 2001; 104(15): 1856 - 1862.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.